Domain Therapeutics has announced the first patients have been dosed in its phase 1/2 DOMISOL clinical trial of […]

$25m milestone payment supports pipeline progress in neurodegenerative disease research

Qureight’s imaging platform validated in peer-reviewed study

Exclusive licensing deal aims to advance promising cancer therapy

Preliminary phase 4 data highlights improvements in sleep, work productivity and quality of life

International registry highlights impact of POTELIGEO in rare lymphoma subtypes

Funding to support phase 2 trial of INNA-051 aimed at preventing viral respiratory infections

Early data from novel immunotherapy drug shows tumour response in resistant cancers

Global Fund welcomes private sector support ahead of phase 8 replenishment summit

Subcutaneous therapy delivers 45 percent response rate in difficult-to-treat patients